Clinical Trials · NCT00191893
Bone Effects of Teriparatide Following Alendronate
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 66
- Start date
- Sep 2003
- Locations
- 2 sites, Austria, Czechia
- Primary endpoint
- conventional histomorphometric parameters (bone turnover, bone formation rate, and bone volume) and microdamage accumulation from iliac crest biopsies.